Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167503 | 0.89 | FBP1 (0.41) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1166258 | 0.88 | ADRB2 (0.46) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1166792 | 0.87 | GSK3B (0.51) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1166941 | 0.82 | HCRTR2 (0.42) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1167225 | 0.82 | ACMSD (0.49) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL2821839 | 0.80 | HTR7 (0.46) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1167288 | 0.80 | GSK3B (0.47) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1166278 | 0.79 | ADORA2A (0.50) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1166823 | 0.77 | FBP1 (0.42) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 | |
| SCHEMBL2820561 | 0.77 | ADORA2A (0.46) | HCRTR2HCRTR1ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903378-B | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2014-03-12 | — | — | CN | claimed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | claimed |
| CN-101903353-B | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2013-04-10 | — | — | CN | claimed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | claimed |
| JP-4656674-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | claimed |
| CN-101903353-A | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | claimed |
| CN-101903378-A | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | claimed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | claimed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | claimed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | claimed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | claimed |
| CN-101903378-B | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2014-03-12 | — | — | CN | disclosed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-101903353-B | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2013-04-10 | — | — | CN | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | HCRTR2 55/4885HCRTR1 53/4885ADRB2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.